Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 242

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 242
---
 upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.

On February 11, 2025, the
Company carried out a 1-for-20 reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.

On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (“ASPAC”), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 (equivalent to 15,000 post Second Reverse Stock Split) Class A Ordinary
Shares to ASPAC.

On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company’s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of
Nasdaq’s listing requirements, including shareholder equity of more than $2.5m, as required in the Panel’s decision letter
dated February 19, 2025.

<div align='center'>F-31</div>

On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant
to a Purchase Agreement dated January 21, 2025 between the Company and GIVF (“Purchase Agreement”), the Company purchased
all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (“MicroSort Acquisition”).
Under the terms of the agreement, the Company acquired the technology for US$5 million, which was satisfied through a combination of
US$750,000 in cash and the issuance of 2,500,000 ordinary shares (as was adjusted to 12,